Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
| Price | $22.39 |
|---|---|
| Market cap | $1.35B |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Exchange | NASDAQ |
| 52-week range | 17.22-25.93 |
| Beta | 0 |
Explore LTGO's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.